Search results
Results from the WOW.Com Content Network
(Reuters) -Shares of British drugmaker GSK dropped more than 9% on Monday, after a Delaware judge allowed more than 70,000 lawsuits alleging its discontinued heartburn drug Zantac caused cancer ...
Wednesday, GSK Plc (NYSE:GSK) reported third-quarter sales of $10.42 billion (8.01 billion Sterling Pounds), down 2% year-over-year and up 2% on constant currency. The analysts estimated sales of ...
Moderna stock gained 14%, shooting up to $48.56 per share Tuesday afternoon. Vaccine-makers Novavax and CureVac similarly rose, soaring 15% and 10%, respectively, while Pfizer gained 2% and GSK ...
The stock was among the bottom performers in the FTSE 100 index and Europe's STOXX 600. It was down around 4.8% at 1432 GMT. Pfizer shares fell about 2% on Wednesday and were down 0.8% at $27.22 ...
GlaxoSmithKline (GSK) closed at $40.03 in the latest trading session, marking a -0.12% move from the prior day. GlaxoSmithKline (GSK) Stock Sinks As Market Gains: What You Should Know Skip to main ...
GSK (GSK) closed the most recent trading day at $31.20, moving -1.36% from the previous trading session.
British drugmaker GSK cut its forecast for 2024 vaccine sales on Wednesday after quarterly revenue from its blockbuster shingles and respiratory syncytial virus (RSV) jabs missed expectations ...
GlaxoSmithKline (GSK) closed at $42.80 in the latest trading session, marking a +0.28% move from the prior day.